63 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
26
Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.
AstraZeneca
38
Tactical Approaches to Interconverting GPCR Agonists and Antagonists.
University of Minnesota
12
Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors.
University of Arizona
18
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Institute of Organic Synthesis
17
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
University of Siena
14
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute of Mit and Harvard
38
From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
Laboratoires Fournier
34
Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships ofa,a-tetrahydropyranylglycine.
Menarini Ricerche
14
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
National Institute of Neuroscienc
2
A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers.
Institute of Mutagenesis and Differentiation
9
Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Cortech
5
Design and synthesis of new linear and cyclic bradykinin antagonists.
Institute De Recherches Servier
35
A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.
Fujisawa Pharmaceutical
24
Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
Fujisawa Pharmaceutical
32
A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.
Fujisawa Pharmaceutical
13
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists.
Novartis Institute For Medical Sciences
17
Synthesis and characterization of bradykinin B(2) receptor agonists containing constrained dipeptide mimics.
University of Montpellier
6
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
University of Montpellier
48
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
Fujisawa Pharmaceutical
22
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
Fujisawa Pharmaceutical
58
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
Fujisawa Pharmaceutical
38
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.
Fujisawa Pharmaceutical
2
Technetium-99m-labeled HOE 140: a potential bradykinin B2 receptor imaging agent.
Zentrale Pharmaforschung
7
Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor.
Sterling Winthrop Pharmaceutical Research Division
20
Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.
Novartis Institute For Medical Sciences
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
21
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Università
4
Synthesis and biological activity of new bradykinin pseudopeptide B1 receptor agonists containing alkylic spacers
TBA
34
A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
China Pharmaceutical University
16
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.
Amgen
25
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
Merck Research Laboratories
65
Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.
Vrije Universiteit Brussel
11
Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.
TBA
8
Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies.
Merck Research Laboratories
11
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
TBA
2
Design and synthesis of novel pyrrolidine-containing bradykinin antagonists.
Johnson & Johnson Pharmaceutical Research & Development
38
Synthesis and structure--activity relationships of aroylpyrrole alkylamide bradykinin (B2) antagonists.
Johnson & Johnson Pharmaceutical Research and Development
3
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
University of Patras
48
Pyridine alkaloids with activity in the central nervous system.
University of Auckland
18
Structure-based design of six novel classes of nonpeptide antagonists of the bradykinin B2 receptor.
Roche Bioscience
2
A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.
University of Montpellier
10
Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.
University of Montpellier
15
1-(2-Nitrophenyl)thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B(2) receptor.
Novartis Institute For Medical Sciences
8
The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold.
Novartis Institute For Medical Sciences
23
Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors.
Hoechst Marion Roussel
11
Cinnamamide: An insight into the pharmacological advances and structure-activity relationships.
National Institute of Pharmaceutical Education and Research (NIPER)
6
Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system.
Scios Nova
9
Design of potent, cyclic peptide bradykinin receptor antagonists from conformationally constrained linear peptides.
Scios Nova
3
NMR and computational evidence that high-affinity bradykinin receptor antagonists adopt C-terminal beta-turns.
Scios Nova
2
A proposed model of bradykinin bound to the rat B2 receptor and its utility for drug design.
Scios Nova
49
Identification and biological evaluation of thiazole-based inverse agonists of RORĪ³t.
Phenex Pharmaceuticals
